Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage (LEVOSAH)
Sub-arachnoid Haemorrhage
About this trial
This is an interventional treatment trial for Sub-arachnoid Haemorrhage focused on measuring Sub-arachnoid haemorrhage, vasospasm, delayed cerebral ischemia, stroke
Eligibility Criteria
Inclusion Criteria: All adult patients (18 to 75 years old), hospitalized in surgical intensive care at Lariboisière Hospital for subarachnoid haemorrhage of aneurysmal origin WFNS clinical score of I to IV and a mFisher score of 3 or 4. Exclusion Criteria: pregnant women contraindications to levosimendan (including hypersensitivity to levosimendan, severe hypotension (mean arterial pressure less than 65 mmHg), tachycardia (heart rate greater than 120 bpm), cardiac mechanical obstructions) severe renal failure (creatinine clearance < 30 ml/min) severe hepatic failure (signs of hepatic encephalopathy) or chronic liver disease history of torsades de pointes pre-existing severe neurovascular pathologies. Moribund patients. Patient not affiliated to social security Patient participating in another interventional research Patients under legal guardianship or curatorship
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
LEVOSIMENDAN
PLACEBO
Experimental : Levosimendan group
Placebo : Comparator group